The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer. October 16th, 2020. Event review

封面

如何引用文章

全文:

详细

The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer was held on 16th October 2020. The French and Russian oncology experts shared information and exchanged experience concerning the application of the first PI3K inhibitor – alpelisib.

作者简介

Irina Poddubnaya

Russian Medical Academy of Continuous Professional Education

编辑信件的主要联系方式.
Email: irinakolyadina@yandex.ru
ORCID iD: 0000-0002-0995-1801

D. Sci. (Med.), Prof., Acad. RAS

俄罗斯联邦, Moscow

Joseph Gligorov

Sorbonne University

Email: or@hpmp.ru

проф. медицинской онкологии в Университете Сорбонны, врач отд-ния медицинской онкологии больницы Тенон (APHP), исполнительный директор Университетского института онкологии (APHP.6)

法国, Paris

Liudmila Zhukova

A.S.Loginov Moscow Clinical Scientific Practical Center of the Department of Health of Moscow

Email: or@hpmp.ru

MD, Ph.D, Professor of RAS, Deputy Director

俄罗斯联邦, Moscow

Elena Kovalenko

Blokhin National Medical Research Center of Oncology

Email: eikovalenko@mail.ru
ORCID iD: 0000-0003-4763-7992

Cand. Sci. (Med.)

俄罗斯联邦, Moscow

M. Frolova

N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation

Email: drfrolova@yandex.ru

канд. мед. наук, ст. науч. сотр. отд-ния клинической фармакологии и химиотерапии 

俄罗斯联邦, Moscow

参考

  1. Состояние онкологической помощи населению России в 2019 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020.[The state of cancer care for the population of Russia in 2019. Ed. A.D. Kaprin, V.V. Starinsky, A.O. Shahzadova. Moscow: Moscow Scientific Research Institute named after P.A. Herzen – branch of the Federal State Budgetary Institution “National Medical Research Center of Radiology” of the Ministry of Health of Russia, 2020 (in Russian).]
  2. Slamon DJ et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med 2020; 382: 514–24.
  3. Im S-A et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med 2019; 381: 307–16.
  4. Sledge G et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy–MONARCH 2A Randomized Clinical Trial. JAMA Oncol 2020; 6 (1): 116–24.
  5. Эл. ресурс: http://cr.rosminzdrav.ru/#!/schema/236 [Available from: http://cr.rosminzdrav.ru/#!/schema/236 (in Russian).]
  6. Sobhani N et al. The prognostic value of PI3K mutational status in breast cancer: A meta-analysis. J Cell Biochem 2018; 119 (6): 4287–92.
  7. Mosele F et al. ESMO Breast Cancer Congress. May 2–4, 2019. Berlin, Germany.
  8. Tolaney et al. AACR Annual Meeting. March 29 – April 3, 2019. Atlanta, GA.
  9. Di Leo A, Johnston S, Seok Lee K et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2018; 19 (1): 87–100.
  10. Moynahan ME, Chen D, He W et al. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2 - advanced breast cancer: results from BOLERO-2. Br J Cancer 2017; 116 (6): 726–30. https://www.pik3ca.com/PI3K-PATHWAY/
  11. Comprehensive molecular portraits of human breast tumours. The Cancer Genome Atlas Network. Nature 2012; 490 (7418): 61–70. doi: 10.1038/nature11412. https://www.hcp.novartis.com/products/piqray/metastatic-breast-cancer/pik3ca-mutation/
  12. Cardoso F et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 2020; 321 (12): 1623–49.
  13. Vasan N et al. Overview of the relevance of PI3K pathway in HR-positive breast cancer. Ann Oncol 2019. 30 (10). doi: 10.1093/annonc/mdz281
  14. Burke J. PNAS, 2013.
  15. Cai L et al. Protective cellular immunity generated by cross-presenting recombinant overlapping peptide proteins. Oncotarget 2017; 8: 76516–24.
  16. Mayer IA et al. A Phase Ib Study of Alpelisib (BYL719), a PI3Ka-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer. Clin Cancer Res 2017; 23 (1): 26–34.
  17. Loi S et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA 2010; 107 (22): 10208–13.
  18. Stemke-Hale K et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008; 68 (15): 6084–91.
  19. Miller TW et al. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 2011; 29 (33): 4452–61.
  20. Bosch A et al. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med 2015; 7 (283): 283ra51.
  21. Miller TW et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010; 120 (7): 2406–13.
  22. Crowder RJ et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 2009; 69 (9): 3955–62.
  23. Miller TW et al. ERa-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov 2011; 1 (4): 338–51.
  24. Arthur L et al. Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer. Breast Cancer Res Treat 2014; 147: 211–9.
  25. Mosele F et al. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol 2020; 31 (3): 377–86.
  26. Hortobagyi G et al. Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. J Clin Oncol 2016; 34 (5): 419–26. doi: 10.1200/JCO.2014.60.1971
  27. Neven (Abstract # PD2-05), SABCS’2018
  28. Courtney KD et al. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010; 28 (6): 1075–83.
  29. Maira SM et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 2012; 11 (2): 317–28.
  30. Dienstmann R et al. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther 2014; 13 (5): 1021–31.
  31. Fritsch C et al. Characterization of the novel and specific PI3Ka inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther 2014; 13 (5): 1117–29.
  32. Ndubaku CO et al. Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a b-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity. J Med Chem 2013; 56 (11): 4597–610.
  33. Andre F et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2019; 380: 1929–40.
  34. Andre F et al. Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC). Ann Oncol 2020; 31 (Suppl. 4): S1142–215. doi: 10.1016/annonc/annonc325
  35. Turner S et al. ESMO 2020. Presentation # 309P – E-poster.
  36. Эл. ресурс: http://cancergenome.ru/ [Available from: http://cancergenome.ru/ (in Russian).]
  37. Эл. ресурс: https://www.nccn.org/professionals/physician_gls/default.aspx [Available from: https://www.nccn.org/professionals/physician_gls/default.aspx (in Russian).]
  38. Świderska E et al. Role of PI3K/AKT Pathway in Insulin-Mediated Glucose Uptake. Blood Glucose Levels 2018.
  39. Rugo H et al. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol 2020; 31 (8): 1001–10. doi: 10.1016/j.annonc.2020.05.001
  40. Piqray [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp, 2019.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Consilium Medicum, 2020

Creative Commons License
此作品已接受知识共享署名-非商业性使用 4.0国际许可协议的许可。
 


##common.cookie##